

The scientific power of Zinc and Carnosine



Zinkcarnosine

Zinc has proved efficient in **improving taste disorders** (1), restoring gastric lining in **gastric ulcers** (2) and **oral mucositis** as a result of cytotoxic radiotherapy and/or chemotherapy (3).

Anti-inflammatory Anti-oxidant functions Increase in heat shock proteins Nutrined Zinkcarnosine is a chelated compound, containing Zinc and Carnosine.

Zinc is a mineral that is part of many enzymes that are critical for cell proliferation during cell repair in epithelial & epidermal lining.

Carnosine enhances the absorption of Zinc and delivers Zinc to tissues in a delayed/extended manner*.

* Choi H.S., Kim E.S., Keum B., Chun H.J., Sung M.-K. Betaine Chemistry, Analysis, Function and Effects. Royal Society of Chemistry. London, UK: 2015. L-Carnosine and Zinc in Gastric Protection; pp. 548–565.

1. Improving taste disorders

Several studies have demonstrated that Zinc supplementation restores taste in those with taste disorders not associated with cancer.



2. Restoring gastric lining in gastric ulcers

Zinc Carnosine is known for its approved use in management of stomach ulcers.



Study 1

258 subjects with confirmed stomach ulcer were assigned to participate in a double-blind comparative study. Cetraxate Hydrochloride was used as the control drug to evaluate more objectively the clinical usefulness of Zinc Carnosine 2x 150 mg/day for 8 weeks.

- symptoms were collected
- endoscopy before and after treatment

Conclusion

In the group receiving 150 mg Zn C/day, symptoms improved with 75% and endoscopic cure rate was 60.4%.

Source: Miyoshi A., Namiki A., Asagi S., Harasawa S., Ooshiba S., Hayakawa K. Clinical Evaluation of Z-103 on Gastric Ulcer–A Multicenter Double–Blind Comparative Study with Cetraxate Hydrochloride. Jpn. Pharm. Ther. 1992; 20: 199–223

Study 2

A randomized, parallel-group, open-label, prospective study was conducted to assess the efficacy and safety of Zn C combined with triple therapy (omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg) and triple therapy alone as therapy to eradicate Helicobacter pylori.

303 subjects were randomly assigned to receive triple therapy + 2x 75 mg Zn C/day or triple therapy alone.

Conclusion

The rate of Helicobacter pylori eradication was significantly higher in the subjects with triple therapy + Zinc Carnosine 2x 75 mg/day.

Source: Tan B., Luo H.Q., Xu H., Lv N.H., Shi R.H., Luo H.S., Li J.S., Ren J.L., Zou Y.Y., Li Y.Q., et al. Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pyloriassociated gastritis: A prospective, multicenter, randomized clinical trial. PLoS ONE. 2017; 12: e0175625. doi: 10.1371/journal.pone.0175625.



3. Oral mucositis = common complication of cytotoxic radiotherapy and/or chemotherapy



Oral mucositis is associated with severe pain, odynophagia, taste disorder and dehydration.

Prospective studies used an oral rinse, 4x/day, kept in mouth for 1 minute or oral administration of Zn C in a suspension with sodium alginate. This dose equated to the recommended Zinc Carnosine dose of 150 mg/day.

Source: Fujiwara M., Suzuki H., Niwa Y., Nakayama M., Shikata T., Odawara S., Takada Y., Kimura T., Kamikonya N., Hirota S. Polaprezinc reduces the severity of radiation-induced mucositis in head and neck cancer patients. Mol. Clin. Oncol. 2015;3:381–386.



Zinkcarnosine

indication	Stomach and esophagus pathology, anti-inflammatory and healing effect on mucosa stomach & esophagus
dosage	1 cap in the morning and 1 cap in the evening before food
packaging	60 vegecaps per container
composition (amount per 2 vegecaps)	Zinc Carnosine - 75 mg

References Zinkcarnosine



Combination carnosine and zinc

Choi H.S., Kim E.S., Keum B., Chun H.J., Sung M.-K. Betaine Chemistry, Analysis, Function and Effects. Royal Society of Chemistry; London, UK: 2015. L-Carnosine and Zinc in Gastric Protection; pp. 548–565

1. Improving taste disorders

Fujii H., Hirose C., Ishihara M., Iihara H., Imai H., Tanaka Y., Matsuhashi N., Takahashi T., Yamaguchi K., Yoshida K. Improvement of Dysgeusia by Polaprezinc, a zinc-L-carnosine, in outpatients receiving cancer chemotherapy. Anticancer Res. 2018 ;38: 6367–6373. doi: 10.21873/anticanres.12995

Sakagami M., Ikeda M., Tomita H., Ikui A., Aiba T., Takeda N., Inokuchi A., Kurono Y., Nakashima M., Shibasaki Y. A zinc-containing compound, Polaprezinc, is effective for patients with taste disorders: Randomized, double-blind, placebo-controlled, multi-center study. Acta Oto Laryngol. 2009; 129: 1115–1120. doi: 10.1080/00016480802552550. [PubMed] [CrossRef] [Google Scholar]

Takaoka T., Sarukura N., Ueda C., Kitamura Y., Kalubi B., Toda N., Abe K., Yamamoto S., Takeda N. Effects of zinc supplementation on serum zinc concentration and ratio of apo/holo-activities of angiotensin converting enzyme in patients with taste impairment. Auris Nasus Larynx. 2010; 37: 190–194. doi: 10.1016/j. anl.2009.07.003. [PubMed] [CrossRef] [Google Scholar]

2. Restoring gastric lining in gastric ulcers

Miyoshi A., Namiki A., Asagi S., Harasawa S., Ooshiba S., Hayakawa K. Clinical Evaluation of Z-103 on Gastric Ulcer–A Multicenter Double–Blind Comparative Study with Cetraxate Hydrochloride. Jpn. Pharm. Ther. 1992; 20: 199–223

Tan B., Luo H.Q., Xu H., Lv N.H., Shi R.H., Luo H.S., Li J.S., Ren J.L., Zou Y.Y., Li Y.Q., et al. Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. PLoS ONE. 2017; 12: e0175625. doi: 10.1371/journal.pone.0175625.

3. Oral mucositis

Fujiwara M., Suzuki H., Niwa Y., Nakayama M., Shikata T., Odawara S., Takada Y., Kimura T., Kamikonya N., Hirota S. Polaprezinc reduces the severity of radiation-induced mucositis in head and neck cancer patients. Mol. Clin. Oncol. 2015; 3: 381–386. [PMC free article] [PubMed] [Google Scholar]

Hayashi H., Kobayashi R., Suzuki A., Ishihara M., Nakamura N., Kitagawa J., Kanemura N., Kasahara S., Kitaichi K., Hara T. Polapre, zinc prevents oral mucositis in patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation. Anticancer Res. 2014; 34: 7271-7277. [PubMed] [Google Scholar]

Ishihama H., Sayo S., Yokoyama T., Ueno M., Ebihara N., Doi Y., Asano K., Kawamata H., Imai H., Ueki K. P1–032, preventive and Therapeutic Effects of Polaprezinc Suspension on Oral Mucosal Injury. Ann. Oncol. 2013; 24: ix68. doi: 10.1093/annonc/mdt460.12.

Watanabe T., Ishihara M., Matsuura K., Mizuta K., Itoh Y. Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. Int. J. Cancer. 2010; 127: 1984–1990. doi: 10.1002/ijc.25200. [PubMed] [CrossRef] [Google Scholar]

Additional references

A Review of Zinc-L-Carnosine and Its Positive Effects on Oral Mucositis, Taste Disorders, and Gastrointestinal Disorders Susan Hewlings1,* and Douglas Kalman2 Life Sci . 1991; 49(23): PL189-94. doi: 10.1016/0024-3205(91)90321-2.

Applicability of zinc complex of L-carnosine for medical use T Matsukura I, H Tanaka Affiliations expand PMID: 10951100

The membrane-stabilizing action of Zinc Carnosine (Z-103) in stress-induced gastric ulceration in rats C H Cho 1, C T Luk, C W Ogle Affiliations expand PMID: 1943472 DOI: 10.1016/0024-3205(91)90321-2 Review Biochemistry (Mosc) . 2000 Jul; 65(7): 817-23.

Zinc Carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes A Mahmood, A J FitzGerald, T Marchbank, E Ntatsaki, D Murray, S Ghosh, R J Playford Nutrients. 2020 Mar; 12(3): 665. Published online 2020 Feb 29. doi: 10.3390/nu12030665 PMCID: PMC7146259 PMID: 32121367

Fujii H., Hirose C., Ishihara M., Iihara H., Imai H., Tanaka Y., Matsuhashi N., Takahashi T., Yamaguchi K., Yoshida K. Improvement of Dysgeusia by Polaprezinc, a zinc-L-carnosine, in outpatients receiving cancer chemotherapy. Anticancer Res. 2018; 38: 6367–6373. doi: 10.21873/anticanres.12995

Fujiwara M., Suzuki H., Niwa Y., Nakayama M., Shikata T., Odawara S., Takada Y., Kimura T., Kamikonya N., Hirota S. Polaprezinc reduces the severity of radiation-induced mucositis in head and neck cancer patients. Mol. Clin. Oncol. 2015; 3: 381–386. [PMC free article] [PubMed] [Google Scholar]

Hayashi H., Kobayashi R., Suzuki A., Ishihara M., Nakamura N., Kitagawa J., Kanemura N., Kasahara S., Kitaichi K., Hara T. Polaprezinc prevents oral mucositis in patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation. Anticancer Res. 2014; 34: 7271–7277. [PubMed] [Google Scholar]

Ishihama H., Sayo S., Yokoyama T., Ueno M., Ebihara N., Doi Y., Asano K., Kawamata H., Imai H., Ueki K. P1–032preventive and Therapeutic Effects of Polaprezinc Suspension on Oral Mucosal Injury. Ann. Oncol. 2013; 24: ix68. doi: 10.1093/annonc/mdt460.12.

Takaoka T., Sarukura N., Ueda C., Kitamura Y., Kalubi B., Toda N., Abe K., Yamamoto S., Takeda N. Effects of zinc supplementation on serum zinc concentration and ratio of apo/holo-activities of angiotensin converting enzyme in patients with taste impairment. Auris Nasus Larynx. 2010; 37: 190–194. doi: 10.1016/j. anl.2009.07.003. [PubMed] [CrossRef] [Google Scholar]

Watanabe T., Ishihara M., Matsuura K., Mizuta K., Itoh Y. Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. Int. J. Cancer. 2010; 127: 1984–1990. doi: 10.1002/ijc.25200. [PubMed] [CrossRef] [Google Scholar]